Sun Pharmaceutical Industries has received a favorable legal ruling in the United States that clears a key hurdle in launching Leqselvi, its much-anticipated treatment for alopecia areata.
Cipla has received a reaffirmed ‘BUY’ rating from Prabhudas Lilladher following a pivotal regulatory development—the USFDA approval of its generic version of Abraxane (gAbraxane).
In a sharp divergence from its pandemic-era highs, Moderna Incorporated finds itself trading at a substantial discount, even as it sharpens focus on a curated pipeline of mRNA-based therapies.
Sun Pharmaceutical and Zydus Lifesciences shares could see pressure on Monday as both companies have issued limited recall for some pharmaceutical products in the US market.
